June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Early Response to Ranibizumab Predictive of Functional Outcome after Dexamethasone for Unresponsive Diabetic Macular Edema
Author Affiliations & Notes
  • Maria Vittoria Cicinelli
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Michele Cavalleri
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Lea Querques
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Alessandro Rabiolo
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Riccardo Sacconi
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
    Department of Ophthalmology, University Hospital of Verona, Verona, Italy
  • Adriano Carnevali
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
    Department of Ophthalmology, University Magna Graecia, Catanzaro, Italy
  • Chiara Giuffre
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Livia Tomasso
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Francesco Bandello
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Giuseppe Querques
    Opthalmology, San Raffaele Scientific Institute, Milano, Italy
  • Footnotes
    Commercial Relationships   Maria Vittoria Cicinelli, None; Michele Cavalleri, None; Lea Querques, None; Alessandro Rabiolo, None; Riccardo Sacconi, None; Adriano Carnevali, None; Chiara Giuffre, None; Livia Tomasso, None; Francesco Bandello, Alcon (C), Alimera (C), Allergan (C), Bausch and Lomb (C), bayer (C), genentech (C), Hoffmann-La Roche (C), Novagali Pharma (C), Novartis (C), pfizer (C), Sanofi-aventis (C), santen (C), Sifi (C), Thea (C), Thrombogenics (C), Zeiss (C); Giuseppe Querques, Alimera Sciences (C), Allergan (C), Bayer Shering-Pharma (C), Heidelberg (C), Novartis (C), Zeiss (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 916. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Maria Vittoria Cicinelli, Michele Cavalleri, Lea Querques, Alessandro Rabiolo, Riccardo Sacconi, Adriano Carnevali, Chiara Giuffre, Livia Tomasso, Francesco Bandello, Giuseppe Querques; Early Response to Ranibizumab Predictive of Functional Outcome after Dexamethasone for Unresponsive Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):916.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the effects of intravitreal dexamethasone implant (Ozurdex®) in patients suffering from diabetic macular edema (DME) on the basis of their visual and functional response to anti-vascular endothelial growth factor (VEGF) loading dose, in order to justify early shift to corticosteroids in poor responders.

Methods : Retrospective clinical practice study. Data of diabetic patients poorly-responder to ranibizumab (RNB) shifted to 0.7mg Ozurdex® implant injection and followed up to 12 months were reviewed. Main outcome was the evaluation of short-term changes after Ozurdex® injection, stratifying patients on the basis of best-corrected visual acuity (BCVA) and central macular thickness (CMT) after RNB loading dose. Secondary outcome was to investigate clinical gain maintenance at long-term follow up.

Results : Overall, 45 eyes of 45 patients (23 males, 51.1%), mean age 69.7±9 years, were included in the analysis. After 3 injections of RNB, 30 eyes (66.7%) had a poor visual response (-4.3±10.7 letters), while 15 eyes (33.3%) disclosed good visual outcome (+13.9±9.2 letters). Patients with poor visual response were associated with limited morphological improvement (p=0.04). After 1 month from Ozurdex®, only poor responders showed relevant increase in BCVA (p=0.006) and reduction in CMT (p=0.002), in comparison to good visual response patients, featuring only minor clinical effects (p=0.3). The same trend was maintained up to 12 months, after a mean of 1.9±1.1 Ozurdex® administrations.

Conclusions : Visual and anatomical responses after RNB loading dose are significant predictors of both early- and long-term visual acuity improvement after switching to corticosteroids in patients with DME unresponsive to anti-VEGF.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×